Kymriah (tisagenlecleucel)

Product Name:

Kymriah (tisagenlecleucel)

Categories: Genetic & Advanced Therapies, Hematology, Oncology

Discover Savings on Your Medication Access

Trusted concierge service, secure process, and real savings for patients in the U.S.

Table of Contents

Kymriah (tisagenlecleucel)

Product Category

Oncology / Genetic Cell Therapy

Brand Name

Kymriah

Generic Name or Biosimilar

No generic or biosimilar available

Active Ingredient

Tisagenlecleucel (autologous T-cell immunotherapy)

Prescription Status

Prescription-only; hospital/clinic-based administration

Targeted Conditions

  • Pediatric and young adult patients ≤25 years with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse
  • Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
  • Adult patients with relapsed or refractory follicular lymphoma (FL)

Off-Label Usage

  • Other relapsed/refractory B-cell malignancies (clinical trial/experimental contexts)

(Off-label use requires strict regulatory approval and specialized monitoring in clinical trial or compassionate use settings.)

Drug Classification Overview

Kymriah is a CD19-directed genetically modified autologous T-cell immunotherapy (CAR-T cell therapy).
Patient T-cells are collected, genetically engineered to express a chimeric antigen receptor (CAR) that targets CD19 on B-cells, expanded ex vivo, and then reinfused into the patient to attack malignant cells.

Manufacturer in the USA, Mexico, and Canada

USA: Novartis Pharmaceuticals Corporation
Mexico: Novartis Farmacéutica S.A. de C.V.
Canada: Novartis Pharmaceuticals Canada Inc.

Available Strengths and Dosage Forms – United States, Mexico, and Canada

Country Comparison – United States vs Mexico and Canada

  • Treatment protocols are aligned internationally for ALL, DLBCL, and FL indications.
  • Administration restricted to certified hospitals/clinics with CAR-T expertise.
  • Cold chain transport and specialized handling required at all stages.

Average Retail Price (Therapy Cost)

Canada: Savings of approx. 20–40% vs U.S. therapy pricing (subject to reimbursement programs)
Mexico: Savings of approx. 30–45% vs U.S. therapy pricing (via certified hospital programs)

Costs vary significantly due to individualized manufacturing, hospitalization, and supportive care requirements.

Where to Buy USA

  • Restricted to certified U.S. CAR-T treatment centers partnered with Novartis

Access requires hematology/oncology specialist referral and insurance or financial support approval.

Storage Requirements

  • Patient-specific infusion product must be stored frozen in vapor-phase liquid nitrogen until prepared for infusion.
  • Handled only by authorized treatment center staff.

Key Benefits

  • Personalized, genetically engineered therapy targeting malignant B-cells
  • Proven efficacy in relapsed/refractory ALL, DLBCL, and FL
  • Potential for durable remission after a single infusion
  • Alternative for patients unresponsive to conventional therapies
  • Represents a breakthrough in personalized oncology

Shipping from Canada

Kymriah is available only through certified Canadian treatment centers regulated by Health Canada. MedicalMex facilitates patient coordination with licensed oncology centers and hospitals authorized to provide CAR-T therapy.

MedicalMex facilitates:

  • Referral coordination with certified CAR-T centers
  • Prescription and treatment plan verification
  • Cross-border medical travel logistics
  • Insurance and payment coordination
  • Patient case management and follow-up support

Buying from Mexico

In Mexico, Kymriah is accessible only in selected certified hospitals under COFEPRIS regulation. MedicalMex coordinates patient access through its verified hospital partners.

MedicalMex facilitates:

  • Travel and accommodation support for patients and families
  • Coordination with licensed hematology/oncology specialists
  • Prescription and CAR-T treatment compliance
  • Case management and bilingual patient support
  • Follow-up and survivorship care logistics

Side Effects

  • Common: Cytokine release syndrome (CRS); Fever; Chills; Fatigue; Headache
  • Moderate: Hypotension; Hypoxia; Neurological effects such as confusion or tremor
  • Serious: Severe CRS; Seizures; Cerebral edema; Life-threatening infections; Prolonged cytopenias

Patients require hospitalization for monitoring and management of cytokine release syndrome and neurological toxicities.

Warnings and Precautions

  • Restricted to certified treatment centers with trained personnel
  • High risk of CRS and neurotoxicity – immediate supportive care required
  • Not indicated for patients with active infection or poor performance status
  • Long-term risk of B-cell aplasia requiring immunoglobulin replacement
  • Pregnancy and breastfeeding: safety not established

Alternative Medications (by Indication)

Other CAR-T therapies: Yescarta (axicabtagene ciloleucel), Breyanzi (lisocabtagene maraleucel), Tecartus (brexucabtagene autoleucel)
Hematopoietic stem cell transplantation (HSCT)
Chemotherapy regimens for relapsed/refractory ALL, DLBCL, or FL

Medication FAQs

Kymriah is a personalized CAR-T cell therapy that uses a patient’s own T-cells to target and destroy cancer cells.

It is administered as a single intravenous infusion after a lymphodepleting chemotherapy regimen, in a certified hospital or clinic.

It is indicated for pediatric/young adult ALL, and adult patients with relapsed/refractory DLBCL or FL.

Yes. Patients are hospitalized during and after infusion for close monitoring and management of side effects.

Yes. It is available in Canada and Mexico, but only at certified treatment centers approved by Health Canada and COFEPRIS.

The most significant risks are cytokine release syndrome (CRS) and neurological toxicities, which require specialized management.

Yes, it is typically given as a one-time infusion, though follow-up and supportive care are essential.

Persistence varies, but CAR-T cells may remain active for months to years, providing durable remission in some patients.

Yes. Kymriah can only be prescribed and administered by a licensed oncologist in a certified treatment center.

Yes. MedicalMex coordinates referrals, travel, and logistics for patients seeking Kymriah therapy in Canada or Mexico.